Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
BioVacSafe Resource Report Resource Website 1+ mentions |
BioVacSafe (RRID:SCR_003745) | BioVacSafe | data or information resource, portal, organization portal, consortium | Project focused on developing cutting edge tools to speed up and improve the testing and monitoring of vaccine safety, both before and after release to the market. The three specific objectives of the project are: * the characterization of early inflammation induced by vaccines currently on the market and the identification and validation of biomarkers of early inflammation and allergic responses; * the identification and validation of early biomarkers of autoimmunity and their use to help identifying population at risk of developing autoimmunity; * the analysis of the incidence and epidemiology of autoimmune disease in the general population and the link to genetic background or previous events in the life of patients, including severe effects, such as anaphylactic shock. | safety, biomarker, consortium, clinical trial, inflammation, vaccine, infection, immunosafety, efficacy, autoimmunity, drug development, drug, test, monitor |
is listed by: Consortia-pedia has parent organization: University of Surrey; Surrey; United Kingdom |
Innovative Medicines Initiative 115308 | nlx_157978 | SCR_003745 | Biomarkers for Enhanced Vaccine Safety, Biovacsafe.eu, Biomarkers for enhanced vaccines immunosafety, Biomarkers for Enhanced Vaccine ImmunoSafety, BioVacSafe Project, BioVacSafe - Biomarkers for enhanced vaccines immunosafety | 2026-08-08 11:58:09 | 7 | |||||||
|
Coca-Cola Company Resource Report Resource Website 1+ mentions |
Coca-Cola Company (RRID:SCR_003749) | Coca-Cola, KO | commercial organization | An American multinational beverage corporation and manufacturer, retailer and marketer of nonalcoholic beverage concentrates and syrups, which is headquartered in Atlanta, Georgia. (Wikipedia) It is the world's largest beverage company, refreshing consumers with more than 500 sparkling and still brands. | beverage | Crossref funder ID: 100004367, ISNI: 0000 0004 0504 2170, grid.451378.c, Wikidata: Q3295867, nlx_158091 | https://ror.org/00yc8qw13 | SCR_003749 | KO, The Coca-Cola Company, Coca-Cola | 2026-08-08 11:58:02 | 2 | ||||||||
|
Seven Hills Bioreagents Resource Report Resource Website 1+ mentions |
Seven Hills Bioreagents (RRID:SCR_003748) | commercial organization | An Antibody supplier | nlx_152458 | SCR_003748 | 2026-08-08 11:58:09 | 3 | ||||||||||||
|
Advanced Immunization Technologies Resource Report Resource Website 1+ mentions |
Advanced Immunization Technologies (RRID:SCR_003741) | ADITEC | data or information resource, portal, organization portal, consortium | A consortium that aims to accelerate the development of immunization technologies for the next generation of human vaccines. The goals are to characterize the mode of action and conduct comparative effectiveness studies of: adjuvants, vectors, formulations, delivery devices, routes of immunization, homologous and heterologous primeboost schedules, on vaccine efficacy. As part of these clinical trials, the consortium will also investigate the impact of host factors such as age, gender, genetics and pathologies. The consortium hopes to use insights gained from their projects to advance the development of next-generation vaccines, using tools such as standardized animal models to select promising immunization technologies. The intended outcome of this partnership is to improve the vaccine development process by advancing: basic research, new technology development, and clinical trial methods. Scientific objectives: # Development of adjuvants, vectors, formulations, and delivery devices # Selection of candidates, routes of immunization, and prime-boost combinations in animal models # Assessment of the impact of host factors in response to vaccination # Development of concepts and tools from human immunization # Development of concepts and tools to address regulatory and ethical issues posed by novel immunization technologies # Creation of an internationally recognized training program for translational immunology and vaccinology. Data is shared across the research partners within and between the different workstreams. Additionally, the consortium has plans to create a clinical database that combines phenotypic and clinical information to study the immune response to influenza vaccination at a population level, in an effort to advance studies into the effects of genetic background, gender, and disease on vaccine response. | drug, consortium, drug development, biomarker, vaccine, immunization, vaccine technology, adjuvant, vector, route, device, prime-boost, host factor, system biology, technology, animal model, human immunology, immunology, phenotype, clinical, clinical trial, public health | is listed by: Consortia-pedia | European Union FP7 280873 | nlx_157968 | SCR_003741 | Advanced Immunization Technologies (ADITEC) | 2026-08-08 11:58:09 | 8 | |||||||
|
ABIRISK Resource Report Resource Website 10+ mentions |
ABIRISK (RRID:SCR_003740) | ABIRISK | data or information resource, portal, organization portal, consortium | A consortium that seeks to provide an integrated approach to anti-drug immunization by evaluating immunogenicity in hemophilia A, multiple sclerosis, and inflammatory diseases, and exploring new tools for protein drug immunogenicity. The data collected will be pooled in a single immunogenicity databank and will be standardized and used to develop models of anti-drug antibodies. By examining the correlation between patient and clinical factors and the incidence of immunogenicity, it hopes to reduce the regulatory and resource burdens of immunogenicity testing. The objectives of the consortium are: # Access to large cohorts of patients treated with marketed biopharmaceutical products # Complementary expertise for anti-drug antibodies (ADA) assays; standardization and characterization of ADA # Novel integrated approaches to characterize anti-drug lymphocyte responses # Development and validation of innovative prediction tools # Collection and integration of immunogenicity-related data and clinical relevance of ADA ABIRISK is grouped into five working projects, which communicate with one another and provide each other with results and data for analysis. The five working projects are: ADA assay development and validation and cohort management; cellular characterization and mechanisms of the AD immune response; evaluation and development of technologies for predicting immunogenicity; establishment of database, data analyses and integration; and project management and communication. | drug, consortium, drug development, biomarker, pharmacogenomics, biopharmaceutical product, immune response, immunogenicity, data sharing, immune system, biopharmaceutical, clinical |
uses: eTRIKS is listed by: Consortia-pedia |
Innovative Medicines Initiative 115303 | nlx_157967 | SCR_003740 | Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk, ABIRISK Project | 2026-08-08 11:58:05 | 17 | |||||||
|
RevMan Resource Report Resource Website 10000+ mentions |
RevMan (RRID:SCR_003581) | RevMan | software resource | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 5, 2023.A software package that does meta-analysis and provides results in tabular format and graphically., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. |
is listed by: OMICtools is listed by: SoftCite |
THIS RESOURCE IS NO LONGER IN SERVICE | OMICS_00244 | SCR_003581 | Review Manager | 2026-08-08 11:58:07 | 12962 | ||||||||
|
Torrey Pines Biolabs Resource Report Resource Website 100+ mentions |
Torrey Pines Biolabs (RRID:SCR_003580) | commercial organization | An Antibody supplier | nlx_152481 | SCR_003580 | Torrey Pines Biolabs Inc., Torrey Pines Biolabs Inc | 2026-08-08 11:58:03 | 376 | |||||||||||
|
Charles Stark Draper Laboratory Resource Report Resource Website 1+ mentions |
Charles Stark Draper Laboratory (RRID:SCR_003736) | Draper | nonprofit organization | A not-for-profit research and development laboratory focused on the design, development, and deployment of advanced technological solutions for the nation's most challenging and important problems in security, space exploration, healthcare, and energy. Their expertise includes the areas of guidance, navigation, and control systems; fault-tolerant computing; advanced algorithms and software solutions; modeling and simulation; and MEMS and multichip module technology. With a strong commitment to delivering working solutions to their sponsors, they apply their expertise to a variety of domains, including autonomous air, land, sea, and space systems; information integration; distributed sensors and networks; precision-guided munitions; and biomedical engineering; chemical/biological defense; and energy system modeling and management. When appropriate for the needs of their sponsors, they will work with commercial partners to transition their technology to commercial production. | engineering, technology, research, defense, space, biomedical, energy, service |
is related to: Massachusetts Institute of Technology; Massachusetts; USA; is parent organization of: Center for Integration of Medicine and Innovative Technology |
Acknowledgement required, Non-commercial | grid.417533.7, Crossref funder ID: 100006353, nlx_157942, ISNI: 0000 0004 0634 6125, Wikidata: Q2876029 | https://ror.org/04378d909 | SCR_003736 | Draper Laboratory, The Charles Stark Draper Laboratory Inc | 2026-08-08 11:58:05 | 1 | ||||||
|
TED Resource Report Resource Website 10+ mentions |
TED (RRID:SCR_003739) | video resource, data or information resource, narrative resource, database, portal | A nonprofit devoted to spreading ideas, usually in the form of short, powerful talks (18 minutes or less). TED began as a conference where Technology, Entertainment and Design converged, and today covers almost all topics - from science to business to global issues - in more than 100 languages. Meanwhile, independently run TEDx events help share ideas in communities around the world. | idea | is parent organization of: TED-Ed | Free | nlx_157959 | SCR_003739 | 2026-08-08 11:58:02 | 13 | |||||||||
|
Ovation Resource Report Resource Website 1+ mentions |
Ovation (RRID:SCR_003737) | Ov | data management software, commercial organization, software resource, software application | A dropbox like model cloud-based, commercial data management and collaboration system designed specifically for research scientists. It helps manage and annotate data, track provenance and share this with colleagues. | cloud based | Free trial, Commercial | SciRes_000172, nlx_158031 | SCR_003737 | 2026-08-08 11:58:09 | 3 | |||||||||
|
OncoTrack Resource Report Resource Website 1+ mentions |
OncoTrack (RRID:SCR_003767) | OncoTrack | data or information resource, portal, organization portal, consortium | An international consortium to develop and assess novel approaches to identify and characterize biological markers for colon cancer that will deepen the understanding of the variable make-up of tumors and how this affects the way patients respond to treatment. They will use cutting edge laboratory-based genome sequencing techniques coupled to novel computer modelling approaches to study both the biological heterogeneity of colon cancers (i.e. patient to patient variability) as well as tumor variation within the patient for example, by comparing primary tumors with metastases. This five year project brings together top scientists from European academic institutions offering a wide range of expertise, and partners them with pharmaceutical companies. The project is based on the premise that this genetic and epigenetic information, combined with a description of the molecular pathology of the tumor, will allow OncoTrack to generate a more accurate in-silico model of the cancer cell. This will facilitate the identification of predictive markers that can be used to guide the optimal therapy strategy at the level of the individual patient - and will also provide on-going prognostic guidance for the clinician. This project will not only advance understanding of the fundamental biology of colon cancers but will provide the means and approach for the identification of previously undetected biomarkers not only in the cancer under study, but potentially also in other solid cancers and, in doing so, open the door for personalized management of the oncology patient. | oncology, biomarker, diagnosis, basic science, genome sequencing, computer modelling, genetic, epigenetic, pathology, model, cancer cell, colon, cancer, treatment, genomics, clinical, systems biology, in-silico model, patient variability, tumor variability |
uses: GenomeWeb uses: eTRIKS is listed by: Consortia-pedia is related to: Roche is related to: Janssen Research and Development is related to: Merck is related to: Pfizer Animal Genetics is related to: Charite - Universitatsmedizin Berlin; Berlin; Germany is related to: Max Planck Institute for Molecular Genetics; Berlin; Germany is related to: Medical University of Graz; Graz; Austria is related to: Paris-Sud University; Paris; France is related to: Dresden University of Technology; Saxony; Germany is related to: University College London; London; United Kingdom is related to: Uppsala University; Uppsala; Sweden is related to: Stockholm University; Stockholm; Sweden is related to: Vall d'Hebron Institute of Oncology; Barcelona; Spain is related to: Alacris Theranostics is related to: Experimental Pharmacology and Oncology Berlin-Buch is related to: GABO:mi is related to: International Prevention Research Institute has parent organization: Max Planck Institute for Molecular Genetics; Berlin; Germany |
Innovative Medicines Initiative ; EFPIA |
nlx_158037 | SCR_003767 | OncoTrack - Methods for systematic next generation oncology biomarker development, Onco Track | 2026-08-08 11:58:06 | 9 | |||||||
|
Predict-TB Resource Report Resource Website 10+ mentions |
Predict-TB (RRID:SCR_003766) | PreDiCT-TB | data or information resource, portal, organization portal, consortium | Consortium to accelerate the search for new, more effective combinations of treatments to tackle Tuberculosis and address pre-clinical research barriers to the discovery and development of new TB drug combinations. To overcome the challenges in Tuberculosis drug development they will create tools to accelerate PK-PD (Pharmacokinetic / Pharmacodynamic) analysis that are connected to clinical outcomes. By addressing the gaps in preclinical information, the consortium aims to provide a framework and tools to facilitate the transition of the best combinations of drugs to late phase development. They aim to develop an integrated set of laboratory-based models that will provide much-needed data to indicate the most appropriate doses and combinations of drugs for patients. In addition, the project will generate a comprehensive database of patient data from previous and on-going clinical trials for use as a reference for evaluating the performance of combination anti-TB drug regimens in these newly developed laboratory models. Ultimately, they aim to enable researchers to be able to use the information generated by the novel models to design better clinical trials involving TB patients. The aims of the consortium: * To systematically evaluate two successive panels of representative anti-tuberculosis drugs (licensed and novel) using a suite of standard, novel and enhanced preclinical model systems, with respect to performance in clinical trials * To refine the set of preclinical systems on the basis of these results in order to identify and define the currently optimal critical path in discovery and pre-clinical development for tuberculosis. * To develop an integrated PK-PD / Disease modelling and simulation framework for tuberculosis which will facilitate prediction of optimal combinations and design of clinical studies. | pre-clinical, drug, bedaquiline, tool development, basic research, drug development, lung, model, simulation, database |
uses: eTRIKS is listed by: Consortia-pedia is related to: Critical Path to TB Drug Regimens is related to: Janssen Research and Development is related to: University of Liverpool; Liverpool; United Kingdom is related to: Ecole Polytechnique Federale de Lausanne; Lausanne; Switzerland is related to: Public Health England; London; United Kingdom is related to: Pasteur Institute is related to: Liverpool School of Tropical Medicine; Liverpool; United Kingdom is related to: Max-Planck-Gesellschaft is related to: St Georges University of London; London; United Kingdom is related to: Charles III University of Madrid; Madrid; Spain is related to: University College London; London; United Kingdom is related to: University of Leicester; Leicester; United Kingdom is related to: University of St Andrews; Scotland; United Kingdom is related to: Uppsala University; Uppsala; Sweden is related to: Microsens is related to: ZF-screens is related to: Max Planck Institute for Infection Biology; Berlin; Germany is related to: Max Planck Institute of Molecular Cell Biology and Genetics; Dresden; Germany is related to: University of Sussex; Brighton; United Kingdom has parent organization: University of Liverpool; Liverpool; United Kingdom |
Innovative Medicines Initiative 115337; EFPIA |
nlx_158036 | SCR_003766 | PreDiCT - TB | 2026-08-08 11:58:03 | 10 | |||||||
|
Stein Institute for Research on Aging Video Archive Resource Report Resource Website 1+ mentions |
Stein Institute for Research on Aging Video Archive (RRID:SCR_003761) | Stein Institute Videos | video resource, data or information resource, narrative resource, podcast | Videos and podcasts presenting the latest innovative research being conducted by the Stein Institute for Research on Aging medical faculty, with the aim of promoting healthy aging. Additionally, many of the public lectures from the Public Lecture Series are also available on UCSD-TV's website video on demand programming. The Lecture series allows affiliated faculty members of the Stein Institute for Research on Aging and other scientists from the UCSD School of Medicine, as well as individuals from surrounding academic and research institutions, to present the latest findings in their respective fields of expertise and share their present work with the general community. All of these lectures focus on topics related to healthy aging or age-related diseases. | late adult human |
uses: UCSD-TV has parent organization: Stein Institute for Research on Aging |
Aging, Healthy aging, Age-related disease | Public, Commercial license | nlx_157990 | SCR_003761 | 2026-08-08 11:58:09 | 1 | |||||||
|
eTRIKS Resource Report Resource Website 10+ mentions |
eTRIKS (RRID:SCR_003765) | eTRIKS | data or information resource, consortium, service resource, portal, organization portal | Research informatics and analytics platform for the IMI OncoTrack consortium. | data sharing, drug discovery, translational research, informatics, knowledge management, metadata standard, platform, analytics, tool development, bio.tools |
uses: tranSMART is used by: U-BIOPRED is used by: Predict-TB is used by: OncoTrack is used by: ABIRISK is used by: RA MAP is listed by: Consortia-pedia is listed by: Debian is listed by: bio.tools is related to: Roche is related to: Janssen Research and Development is related to: Merck is related to: Pfizer Animal Genetics is related to: Imperial College London; London; United Kingdom is related to: French National Center for Scientific Research is related to: Clinical Data Interchange Standards Consortium is related to: University of Luxembourg; Luxembourg; Luxembourg is related to: IDBS is related to: BioSci Consulting is related to: TraIT is related to: EMIF is related to: Open PHACTS has parent organization: Imperial College London; London; United Kingdom |
Innovative Medicines Initiative ; EFPIA |
PMID:29482119 | biotools:eTRIKS, nlx_158034 | https://bio.tools/eTRIKS | SCR_003765 | European Translational Information and Knowledge Management Services, European Translational Information & Knowledge Management Services | 2026-08-08 11:58:09 | 11 | |||||
|
mzML Resource Report Resource Website 10+ mentions |
mzML (RRID:SCR_003763) | mzML | data or information resource, standard specification, narrative resource, markup language, interchange format | Markup language for encoding raw spectrometer output. From 2005-2008 there has existed two separate XML formats for encoding raw spectrometer output: mzData developed by the PSI and mzXML developed at the Seattle Proteome Center at the Institute for Systems Biology. It was recognized that the existence of two separate formats for essentially the same thing generated confusion and required extra programming effort. Therefore the PSI, with full participation by ISB, has developed a new format by taking the best aspects of each of the precursor formats to form a single one. It is intended to replace the previous two formats. This new format was originally given a working name of dataXML. The final name is mzML. | mass spectrometry, specification |
is used by: Mspire-Simulator is related to: pymzML has parent organization: HUPO Proteomics Standards Initiative |
nlx_158004 | SCR_003763 | mzML Specification | 2026-08-08 11:58:05 | 24 | ||||||||
|
TI Pharma Resource Report Resource Website 10+ mentions |
TI Pharma (RRID:SCR_003758) | TI Pharma | data or information resource, organization portal, consortium, portal, funding resource | A not-for-profit organization that initiates and manages drug development consortia that involve the pharmaceutical industry, academia, and the Dutch Government. The aim of all their consortia is to conduct pre-competitive research while strengthening the Netherlands' international reputation for drug development. The consortia are focused on addressing therapeutic areas that are listed as priority areas by the World Health Organization including: autoimmune diseases, cardiovascular diseases, cancer, infectious diseases, and diseases of the brain. The consortia are also focused on enabling: therapeutic target discovery, validation, and animal models; lead selection and in-silico modeling; predictive drug disposition and toxicology; biomarkers and biosensors; drug formulation, delivery, and targeting; and, production technologies. TI Pharma consortia aim to improve the efficiency of the drug-development process, with a focus on advancing regulatory science. In addition to research, TI Pharma also has objectives to train and educate scientists in the Netherlands on the drug discovery and development processes, as well as on entrepreneurship. Participants include: all Dutch universities and academic medical centers, more than 30 industrial partners, small-to-medium sized companies, and representatives from the Dutch Medicines Evaluation Board (Netherlands regulatory body for drugs). | consortium, biomarker, drug, drug development, tool development, pharmaceutics, drug discovery, animal model, biosensor, drug formulation, drug delivery, drug target, medicine |
is listed by: Consortia-pedia is related to: European Lead Factory is related to: Kinetics for Drug Discovery is parent organization of: Towards novel translational safety biomarkers for adverse drug toxicity is parent organization of: European Lead Factory is parent organization of: Kinetics for Drug Discovery |
Dutch government ; industry ; academia |
nlx_157987 | SCR_003758 | Stichting Top Instituut Pharma, Top Industry Pharma, Top Institute Pharma, Foundation Top Institute Pharma | 2026-08-08 11:58:03 | 12 | |||||||
|
PyroBayes Resource Report Resource Website 1+ mentions |
PyroBayes (RRID:SCR_003757) | PyroBayes | software resource | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 6, 2023. A base caller for pyrosequences from the 454 Life Sciences sequencing machines. | is listed by: OMICtools | PMID:18193056 | THIS RESOURCE IS NO LONGER IN SERVICE | OMICS_01155 | SCR_003757 | 2026-08-08 11:58:09 | 3 | ||||||||
|
Oxford Nanopore Technologies Resource Report Resource Website 100+ mentions |
Oxford Nanopore Technologies (RRID:SCR_003756) | Oxford Nanopore | commercial organization | Commercial organization developing a disruptive, proprietary technology platform for the direct, electronic analysis of single molecules. The instruments GridION and MinION are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule. Consequently, the platform has a broad range of potential applications, including scientific research, personalized medicine, crop science and security / defence. | nanopore technology, dna, rna, protein, small molecule, molecule, analysis, nanopore, nanopore sensing |
is related to: READNA is related to: Pychopper |
nlx_158233 | SCR_003756 | Oxford Nanopore Technologies Ltd | 2026-08-08 11:58:05 | 448 | ||||||||
|
Stein Institute for Research on Aging Resource Report Resource Website |
Stein Institute for Research on Aging (RRID:SCR_003759) | Stein Institute | data or information resource, portal, training resource, topical portal | Portal dedicated to the development and application of the latest advances in biomedical and behavioral science knowledge to issues of successful, healthy aging and the prevention and reduction of the burden of disability and disease in late life. Additionally, they provide numerous grants to junior faculty, as well as education programs for doctors and researchers through monthly Grand Rounds. From studying memory to identifying genes with important roles in aging, Stein Institute scientists are continuously pushing the boundaries of knowledge. One of their most promising ongoing projects is the Successful AGing Evaluation (SAGE) Study. SAGE is the only large-scale study on successful aging that considers the impact of positive psychological traits, such as resilience and wisdom, in addition to biological factors, providing a much more complete picture of older adults. Their monthly public lectures presented by renowned physicians and scientists are broadcast on UCSD-TV and have been viewed more than one billion times. This year they partnered with the Clinical and Translational Research Institute and the Osher Lifelong Learning Institute to organize Making Sense of Science, a course for older adults interested in science and health. In addition, They distribute a free monthly newsletter and work extensively with the community, participating in numerous events and conferences. | neuroscience, lecture, article, funding resource, late adult human |
has parent organization: University of California San Diego School of Medicine; California; USA is parent organization of: Stein Institute for Research on Aging News is parent organization of: Stein Institute for Research on Aging Video Archive |
Aging, Healthy aging | Public | nlx_157988 | SCR_003759 | UCSD Stein Institute for Research on Aging, Sam and Rose Stein Institute for Research on Aging, Center for Healthy Aging Stein Institute for Research on Aging | 2026-08-08 11:58:05 | 0 | ||||||
|
NIH Blueprint for Neuroscience Research Resource Report Resource Website 10+ mentions |
NIH Blueprint for Neuroscience Research (RRID:SCR_003670) | NIH Blueprint, Blueprint, | data or information resource, training resource, topical portal, portal, funding resource | Collaborative framework that includes the NIH Office of the Director and the 14 NIH Institutes and Centers that support research on the nervous system. By pooling resources and expertise, the Blueprint identifies cross-cutting areas of research, and confronts challenges too large for any single Institute or Center. The Blueprint makes collaboration a day-to-day part of how the NIH does business in neuroscience, complementing the basic missions of Blueprint partners. During each fiscal year, the partners contribute a small percentage of their funds to a common pool. Since the Blueprint's inception in 2004, this pool has comprised less than 1 percent of the total neuroscience research budget of the partners. In 2009, the Blueprint Grand Challenges were launched to catalyze research with the potential to transform our basic understanding of the brain and our approaches to treating brain disorders. * The Human Connectome Project is an effort to map the connections within the healthy brain. It is expected to help answer questions about how genes influence brain connectivity, and how this in turn relates to mood, personality and behavior. The investigators will collect brain imaging data, plus genetic and behavioral data from 1,200 adults. They are working to optimize brain imaging techniques to see the brain's wiring in unprecedented detail. * The Grand Challenge on Pain supports research to understand the changes in the nervous system that cause acute, temporary pain to become chronic. The initiative is supporting multi-investigator projects to partner researchers in the pain field with researchers in the neuroplasticity field. * The Blueprint Neurotherapeutics Network is helping small labs develop new drugs for nervous system disorders. The Network provides research funding, plus access to millions of dollars worth of services and expertise to assist in every step of the drug development process, from laboratory studies to preparation for clinical trials. Project teams across the U.S. have received funding to pursue drugs for conditions from vision loss to neurodegenerative disease to depression. Since its inception in 2004, the Blueprint has supported the development of new resources, tools and opportunities for neuroscientists. For example, the Blueprint supports several training programs to help students pursue interdisciplinary areas of neuroscience, and to bring students from underrepresented groups into the neurosciences. The Blueprint also funds efforts to develop new approaches to teaching neuroscience through K-12 instruction, museum exhibits and web-based platforms. From fiscal years 2007 to 2009, the Blueprint focused on three major themes of neuroscience - neurodegeneration, neurodevelopment, and neuroplasticity. These efforts enabled unique funding opportunities and training programs, and helped establish new resources including the Blueprint Non-Human Primate Brain Atlas. | animal model, collaboration, computational biology, imaging tool, initiative, neurodegeneration, neurodevelopment, neuroinformatics, brain, brain disorder, pain, drug, nervous system disorder, neurotherapeutics, neuroplasticity, neuroscience |
has parent organization: National Institutes of Health is parent organization of: CRE Driver Network is parent organization of: Blueprint Neurotherapeutics Network is parent organization of: National Center for Complementary and Alternative Medicine is parent organization of: National Eye Institute (NEI) Commons is parent organization of: National Institute of Biomedical Imaging and Bioengineering is parent organization of: National Institute of Nursing Research is parent organization of: National Institute on Alcohol Abuse and Alcoholism is parent organization of: National Institute on Drug Abuse is parent organization of: National Institute on Deafness and Other Communication Disorders is parent organization of: National Institute of General Medical Sciences is parent organization of: National Institute of Dental and Craniofacial Research is parent organization of: Office of Behavioral and Social Sciences Research is parent organization of: National Institute of Child Health and Human Development is parent organization of: National Institute of Environmental Health Sciences is parent organization of: National Institute of Mental Health is parent organization of: National Institute on Aging is parent organization of: National Institute of Neurological Disorders and Stroke is parent organization of: NeuroImaging Tools and Resources Collaboratory (NITRC) |
nif-0000-00219 | SCR_003670 | Neuroscience Blueprint | 2026-08-08 11:58:04 | 10 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the ASWG Resources search. From here you can search through a compilation of resources used by ASWG and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that ASWG has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on ASWG then you can log in from here to get additional features in ASWG such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into ASWG you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
Welcome to the ASWG Community.
Our Information
